CTRI/2020/12/029849尚未招募未知
Efficacy and Safety of B Cell Targeted Low Dose Rituximab in Primary Membranous Nephropathy: Prospective Single Arm Interventional Study (A Pilot Study)
il0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patients aged 18 years and older.
- •Patients with diagnosis of Membranous nephropathy proven with renal biopsy (light microscopy and immunofluorescence microscopy) who are not responsive to conservative therapy after 3 months24 or who develop complications related to nephrotic syndrom.11
- •Newly diagnosed patients or previously treated patients of membranous nephropathy presenting with relapse.
- •Estimated GFR >=30 mL/min/1.73 m2 (CKD-EPI formula).
排除标准
- •Patients with underlying disorder (e.g. Hepatitis B and C, HIV, Systemic Lupus Erythematosus, medications causing membranous nephropathy, malignancies).
- •History of hypersensitivity or allergic reaction to rituximab.
- •Patients with life threatening complications of nephrotic syndrome like pulmonary embolism.
- •Patients with rapid deterioration of renal function, not explained otherwise.
- •Active infection/sepsis.
- •Pregnancy or breast feeding.
研究者
相似试验
进行中（未招募）
不适用
Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren diseasePreviously treated patients with primary Sjögrens diseaseMedDRA version: 8.0Level: PTClassification code 10040767EUCTR2005-004740-31-DKniversity of Copenhagen34
进行中（未招募）
不适用
Estudio de los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide (Estudio TESICE-AR).Study of the B-cell-targeted therapy (rituximab) effects on the synovial tissue inmunopathology and peripheral blood B cells in rheumatoid arthritis (TESICE-AR study).Se estudiaran los efectos de la terapia anti-célula B (rituximab) sobre la inmunopatología del tejido sinovial y las células B de sangre periférica en artritis reumatoide.MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2007-003623-20-ESDr. Juan D. Cañete Crespillo, Hospital Clínic de Barcelona
尚未招募
不适用
Efficacy of B cell-targeted therapy in autoimmune bullous diseasesautoimmune bullous diseasesblistering diseases10014982NL-OMON51059niversitair Medisch Centrum Groningen200
尚未招募
2 期
Comparing Use of B-cell depletion therapy to Immunoglobulin in Chronic inflammatory demyelinating polyneuropathy (CUBIC) clinical trial.Chronic inflammatory demyelinating polyneuropathy (CIDP).Inflammatory and Immune System - Autoimmune diseasesNeurological - Other neurological disordersACTRN12623001336673Western Sydney Local Health District35
进行中（未招募）
1 期
Personalized dosing of ocrelizumab in MSMultiple sclerosisEUCTR2021-004791-34-NLVU medical center296